

Original article

Optical Coherence Tomography Findings in Patients With Stent Thrombosis



Javier Cuesta, Fernando Rivero, Teresa Bastante, Marcos García-Guimaraes, Paula Antuña, Teresa Alvarado, Gonzalo Navarrete, Amparo Benedicto, and Fernando Alfonso*

Servicio de Cardiología, Hospital Universitario de La Princesa, Madrid, Spain

Article history:

Received 5 September 2016
Accepted 20 February 2017
Available online 9 May 2017

Keywords:

Stent thrombosis
Stent restenosis
Optical coherence tomography
Angiography
Coronary intervention

ABSTRACT

Introduction and objectives: Stent thrombosis (ST) is a rare but potentially serious complication. Optical coherence tomography (OCT) provides high-resolution images and additional information to angiography in the study of this event.

Methods: Prospective study of patients with ST undergoing reintervention with OCT imaging.

Results: The study included a total of 40 consecutive patients with ST. Mean age was 69 ± 13 years and 83% were male. Early ST (≤ 30 days) was observed in 16 patients and late ST (> 30 days) in 24 patients. Stent thrombosis occurred in 17 bare-metal stents and 23 drug-eluting stents. In 34 patients (85%), adequate OCT images were obtained at the time of the ST. The predominant mechanism in early ST was stent malapposition (39%). In late ST, high frequencies of uncovered (46%) and malapposed struts (17%) were observed, especially in patients with drug-eluting stents. Furthermore, the presence of neoatherosclerosis was very high (67%) in patients with late ST. After intervention, improvements were observed in malapposition length and the amount of residual thrombus.

Conclusions: OCT allows identification of the underlying mechanisms potentially involved in ST. This imaging modality is helpful in guiding reintervention in these patients, which improves the area and length of malapposition, as well as the maximal residual thrombus area.

© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Tomografía de coherencia óptica de pacientes con trombosis del stent

RESUMEN

Introducción y objetivos: La trombosis del stent (TS) es una complicación infrecuente pero potencialmente grave. La tomografía de coherencia óptica (OCT) ofrece imágenes de alta resolución e información adicional a la angiografía en el estudio de esta enfermedad.

Métodos: Estudio prospectivo en el que se incluyó a todos los pacientes con una TS a los que se realizó una OCT durante el procedimiento.

Resultados: Se incluyó a un total de 40 pacientes con TS consecutivos, con una media de edad de 69 ± 13 años; el 83% eran varones. Las TS fueron precoces (≤ 30 días) en 16 pacientes y tardías (> 30 días) en 24. En 17 pacientes la TS se produjo en stents convencionales y en 23, en farmacoactivos. En 34 casos (85%) se realizó estudio con OCT en el momento de la TS. En las TS precoces, el mecanismo predominante (39%) fue la malposición del stent. En las TS tardías se observaron frecuentemente (46%) struts no recubiertos y áreas de malposición (17%), especialmente en pacientes con stents farmacoactivos. Además, la presencia de neoateroesclerosis fue muy elevada (67%) en los pacientes con TS tardía. Tras la intervención se observó una mejora en la longitud de la malposición y la cantidad de trombo en el stent.

Conclusiones: La OCT permite conocer los mecanismos subyacentes potencialmente implicados en la TS y guiar el intervencionismo en estos pacientes. La reintervención disminuye el área y la longitud de la malposición, así como la cantidad de trombo residual.

© 2017 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Palabras clave:

Trombosis del stent
Reestenosis del stent
Tomografía de coherencia óptica
Angiografía
Intervencionismo coronario

SEE RELATED CONTENT:

<http://dx.doi.org/10.1016/j.rec.2017.06.014>, Rev Esp Cardiol. 2017;70:1036-1038.

* Corresponding author: Servicio de Cardiología, Hospital Universitario de La Princesa, Diego de León 62, 28006 Madrid, Spain.
E-mail address: falf@hotmail.com (F. Alfonso).

<http://dx.doi.org/10.1016/j.rec.2017.04.001>

1885-5857/© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Abbreviations

BMS: bare-metal stent
 DES: drug-eluting stent
 OCT: optical coherence tomography
 SEI: stent expansion index
 ST: stent thrombosis

INTRODUCTION

Stent thrombosis (ST) is a rare but serious complication of interventional cardiology, with an incidence of about 1%.^{1–5} Even with appropriate early treatment, this event is associated with high morbidity and mortality.^{1–5} There are 4 categories of ST: acute (< 24 hours), subacute (from 24 hours to ≤ 30 days), late (from 30 days to 1 year), and very late (> 1 year).^{3–5} Its pathophysiological mechanism is highly variable.^{1–5} Previous studies have identified different pathological mechanisms, depending on whether the ST occurs in a bare-metal stent (BMS) or a drug-eluting stent (DES), in addition to the time from stenting to the clinical event.^{3–5} Several studies have determined that the main causes of early ST (acute and subacute, ≤ 30 days) are stent underexpansion and/or malapposition. At the same time, neoatherosclerosis with plaque rupture could play a crucial role in very late ST.^{3–5}

Conventional angiography is insufficient to determine the underlying intimal factors leading to ST. Various researchers have used intracoronary ultrasound to obtain additional morphological information and detect mechanical problems in these patients.⁴ Most of these problems cannot be detected with angiography.^{4–9} More recently, optical coherence tomography (OCT), a technique with better resolution and image quality, has enabled much more accurate analysis of the possible causes of ST. However, due to the rarity of this complication, few data are available.^{10,11}

The aim of this work was to study the use of OCT in patients who experience ST by analyzing all data that could help to identify the anatomical characteristics potentially related to this alarming complication.

METHODS

Patients and Interventions

The present study enrolled all consecutive patients admitted to our center with a diagnosis of ST from October 2013 to March 2016. During this time, a prospective and systematic protocol was applied that included OCT scans before and after the procedure. The overriding concern was to ensure patient safety, and OCT was only performed when permitted by patients' clinical and hemodynamic status. Patients with a TIMI (Thrombolysis in Myocardial Infarction) flow of 0 to 1 after intracoronary administration of nitroglycerin and angioplasty guidewire crossing systematically underwent thrombus aspiration with a 6-Fr device. If this maneuver failed to achieve an adequate antegrade flow, a small-diameter balloon (≤ 2 mm) was advanced to the occluded segment and inflated at low pressures.

No specific criteria were established to guide the interventions, and the treatment used in each patient was chosen by the interventional cardiologist.

Stent thromboses were diagnosed according to the criteria of the Academic Research Consortium.¹² All included patients met the angiographic criteria for “definite” ST and were treated in accordance with the clinical practice guidelines for revascularization.¹

All participants were explained the study protocol and signed informed consent. The study was approved by the ethics committee of the hospital.

Optical Coherence Tomography

All OCT studies were performed with an OCT Frequency Domain system (Dragon Fly, Light Lab, St Jude Medical; St Paul, Minnesota, United States) via a nonocclusive technique by advancing the catheter 10 mm distal to the stent.

All OCT sequences obtained were first assessed to confirm that their quality was sufficient for subsequent analyses. Metallic struts were visible as brilliant structures with high signal intensity and dorsal shadowing. Reference vessel measurements were taken 5 to 10 mm from the stent edges; effort was made to select the least affected section.^{4,13} Subsequently, a quantitative morphometric analysis was performed, with measurements of the cross-sectional area and diameter. The luminal and stent areas were measured throughout the length of the stent at 1-mm intervals. The minimal lumen area and minimal stent area were determined before and after the intervention. The mean reference area was calculated as the mean of the proximal and distal reference areas. If the pullback did not include images of the proximal and distal segments, the visible reference area alone was used. The stent expansion index (SEI) was calculated as the minimal stent area divided by the mean reference area.¹³

Thrombus presence, strut coverage and malapposition, and neoatherosclerosis presence were assessed in all cross-sections.¹³ All sections with thrombi blocking adequate study of at least 2 quadrants of the vessel circumference were excluded. The maximal thrombus area was studied in the cross-section showing the greatest amount of intraluminal thrombi. Struts were considered to be uncovered (classically considered nonendothelialized) if any part of the strut appeared to be directly exposed to the vessel lumen, and the number of cross-sections showing at least 1 uncovered stent strut was counted. Struts were considered malapposed when the axial distance between the surface of the stent and the surface of the vessel was greater than the thickness of the strut. An “image to image” longitudinal analysis was performed that counted the number of sections with at least 1 stent strut showing poor apposition, and the maximal area and diameter of the malapposition was determined. At the same time, the maximal malapposition length was obtained from a longitudinal view of the image.^{13–15}

Neointimal atherosclerotic changes (neoatherosclerosis) were defined as the presence of: *a*) lipid tissue within the stent (defined as a region with low signal and diffuse edges that caused sufficient signal attenuation to shadow stent struts); *b*) fibroatheroma (both thin-cap [≤ 65 μm] and thick-cap [> 65 μm]); or *c*) neointimal calcification.

Given that some previous studies indicated that the pathophysiological mechanism underlying ST varies according to the time since implantation,^{3–5} the sample was divided into 2 main groups: early ST (≤ 30 days) and late ST (> 30 days). In addition, the most likely underlying cause of the ST was also evaluated, which was generally associated with the region of most thrombosis. The possible ST mechanisms were the following: stent malapposition, severe stent underexpansion, neoatherosclerosis, proximal or distal edge dissection, and plaque rupture in the coronary segment adjacent to the stent. Another potential cause of late ST was a lack of strut coverage.

Statistical Analysis

Continuous variables are presented as the mean \pm standard deviation or as the median [interquartile range], depending on their distribution. Normality was determined using the Kolmogorov-Smirnov test. The Student *t* test or median test (continuous variables) and the chi-square test, Fisher exact test, or McNemar test (qualitative variables) were used to determine differences between groups. *P* < .05 was considered statistically significant.

RESULTS

Baseline Characteristics

Patients' baseline characteristics are summarized in Table 1. The study included 40 consecutive patients diagnosed with definite ST. The mean age was 69 years, 83% were men, and there was a high prevalence of cardiovascular risk factors (Table 1). Most of the thrombosed stents were DESs (58%). The most frequent clinical presentation was ST-segment elevation acute myocardial infarction (*n* = 30; 75%), with TIMI flow 0 (*n* = 32; 80%), and the most frequently affected vessel was the anterior descending artery (*n* = 19; 48%). No significant differences in clinical characteristics were seen between patients with early ST (\leq 30 days) and those with late ST ($>$ 30 days), except for a higher frequency of hypertensive patients in the early ST group. The most frequently used final treatments of the ST were implantation of a new stent (*n* = 18; 45%) and balloon dilatation alone (*n* = 13; 33%) (Table 1).

Baseline OCT was performed in 35 patients admitted with ST (14 with early ST and 21 with late ST). In 1 patient with early ST, the quality of the baseline OCT images was insufficient for their interpretation due to a blood artifact and considerable thrombosis. Thus, the results of 34 patients were finally analyzed. In 77% of patients, thrombus aspiration and/or balloon predilatation were required to achieve a TIMI distal flow score of 2 and obtain OCT images of sufficient quality. Representative OCT images from patients with ST are shown in Figure 1.

The data obtained with OCT are reported in Table 2. Before treatment, the mean reference area was 6.0 ± 2.2 mm² and the minimal stent area was 5.9 ± 2.6 mm². After treatment, there was a slight rise in the minimal stent area (6.0 ± 2.7 mm²; *P* = .59), an increase that was somewhat higher in the subgroup of patients with early ST (from 5.4 ± 2.2 mm² to 5.8 ± 2.1 mm²; *P* = .29) (Table 2). The number of patients with an SEI < 0.8 also decreased, again without statistical significance. An SEI < 0.8 was seen in 24% of patients (*n* = 8) before the treatment vs 15% (*n* = 5) after the intervention. In addition, there was a trend for a decreased percentage of cross-sections showing malapposed struts after the intervention ($6.8\% \pm 11.9\%$ before intervention vs $4.2\% \pm 7.0\%$ after; *P* = .2) and a decreased malapposition area (0.87 ± 0.80 mm² vs 0.45 ± 0.60 mm²; *P* = .15). There was also a significant decrease in the malapposition length (2.93 ± 1.70 mm vs 1.43 ± 1.70 mm; *P* = .015).

Thrombus burden significantly decreased after treatment (maximal thrombus area, 2.5 ± 1.6 mm² before treatment vs 1.4 ± 1.5 mm² after; *P* < .001). These outcomes were seen in both patients with early ST (2.6 ± 1.6 mm² vs 1.7 ± 1.4 mm²; *P* = .006) and those with late ST (2.3 ± 1.6 mm² vs 1.0 ± 1.6 mm²; *P* < .001).

In 8 patients (25%), plaque rupture was seen adjacent to the stent. In all patients, the angiographic imaging was that of a classic ST that met the criteria of the Academic Research Consortium. All of these patients had late ST (4 BMSs and 4 DESs), generally very late (5 patients). In all, the plaque rupture was seen in the coronary segment proximal to the stent and, in

4 of these, was found $>$ 5 mm from the proximal edge of the stent. In most of these patients, there were no signs of stent complications, although alterations to the proximal edge could not be completely ruled out in 2 patients due to the presence of thrombotic material with dorsal shadowing (Figure 2).

No complications were detected that could be directly or indirectly attributed to the use of OCT. Overall in-hospital mortality was 15% (*n* = 6), 13% (*n* = 5) of cardiovascular origin, without differences according to ST time.

Early Thrombosis

Of the 16 patients who experienced early ST, 5 had a single BMS and 11 had a single DES (Table 1). There were no significant differences in clinical or angiographic variables between the 2 subgroups (Table 1). Optical coherence tomography images of sufficient quality were obtained from 13 of these patients (81%) (Table 2). The most frequently observed findings were malapposition, severe underexpansion, and edge dissection (Figure 3).

Late Thrombosis

Of the 24 patients who experienced late ST, 12 had a single BMS and 12 had a single DES (Table 1). There were no differences in clinical or angiographic variables between late and very late thromboses. Optical coherence tomography images of sufficient quality for analysis were obtained from 21 of these patients (88%) (Table 2). Strut coverage and malapposition data according to stent type are shown in Table 3. Most patients with late ST in a DES showed at least 1 section with uncovered struts while a third of patients had signs of malapposition. In contrast, in late STs in BMSs, only 3 patients had sections with uncovered struts while no patients had signs of malapposition. In addition, image analysis revealed that the group of patients with a DES had a significantly higher percentage of uncovered and malapposed struts. Of the 11 patients with late STs lacking strut coverage, 6 of the STs occurred more than 7 years after implantation.

Finally, most patients with late ST showed neoatherosclerosis (*n* = 14; 67%). No differences were seen in the presence of this phenomenon according to stent type (BMS vs DES). Notably, neoatherosclerosis was found to be associated with the region with the highest amount of thrombosis in 11 of the patients. In addition, in most of the patients with neoatherosclerosis (*n* = 9), the time elapsed since implantation was $>$ 5 years. Stent calcification was frequent (50% of patients). Finally, patients with neoatherosclerosis showed a higher percentage of intimal rupture (93% vs 71%).

DISCUSSION

The incidence of ST has decreased in recent years due to improvements in newer-generation stents and advances in concomitant antiplatelet therapy.⁵ However, ST continues to be a gravely serious condition because abrupt thrombotic occlusion of a vessel is associated with extensive infarctions and high mortality.⁴ Consequently, understanding of the pathophysiological mechanisms underlying this process is vital, with OCT able to provide unique information on the underlying substrate.

The main results of our study are the following: a) use of OCT during ST is safe and feasible and provides singular data on the substrate that cannot be obtained using conventional angiography; b) OCT can guide reinterventions, decrease malapposition length, and visualize the decrease in thrombus burden; c) in a not insignificant number of patients, images were obtained of plaque rupture adjacent to the stent; d) in early STs, the main finding was

Table 1
Baseline and Angiographic Characteristics of Patients With Stent Thrombosis

	All	Early ST		P	Late ST		P
		Acute (< 24 h)	Subacute (24 h-30 d)		Late (> 30 d-1 y)	Very late (> 1 y)	
Patients, no.	40	6	10		4	20	
Age, y	69 ± 13	67 ± 10	73 ± 16	NS	70 ± 15	66 ± 11.4	NS
Men	33 (83)	5 (83)	7 (70)	NS	3 (75)	18 (90)	NS
Hypertension	27 (68)	5 (83)	9 (90)	NS	0	13 (65)	*
Dyslipidemia	24 (60)	4 (67)	5 (50)	NS	1 (25)	14 (70)	NS
Diabetes mellitus	15 (38)	1 (17)	6 (60)	*	1 (25)	7 (35)	NS
Smoker	16 (40)	3 (50)	1 (10)	*	1 (25)	11 (55)	NS
Previous AMI	10 (25)	2 (33)	2 (20)	NS	1 (25)	5 (25)	NS
Previous coronary surgery	3 (8)	0	1 (10)	NS	0	2 (10)	NS
Renal failure	4 (10)	1 (17)	1 (10)	NS	1 (25)	1 (5)	NS
Clinical presentation							
Unstable angina	1 (3)	0	0	NS	1 (25)	0	NS
NSTEMI	9 (23)	0	3 (30)	NS	2 (50)	4 (20)	NS
STEMI	30 (75)	6 (100)	7 (70)	NS	1 (25)	16 (80)	NS
Maximum CK	1413 ± 2097	960 ± 831	1067 ± 890	NS	229 ± 168	1958 ± 2780	NS
Maximum hsTnT	4249 ± 5359	3768 ± 5325	3773 ± 4913	NS	800 ± 557	5196 ± 5993	NS
Bare-metal stent	17 (43)	2 (33)	3 (30)	NS	0	12 (60)	*
DEs							
First-generation DEs	4 (10)	0	0	NS	0	4 (20)	NS
Second-generation DEs	12 (30)	2 (33)	6 (60)	NS	2 (50)	2 (10)	NS
Bioabsorbable stents	4 (10)	2 (33)	1 (10)	NS	0	1 (5)	NS
Unknown	3 (8)	0	0	NS	2 (50)	1 (5)	NS
Stent diameter, mm	3 ± 0.5	3.4 ± 0.6	2.9 ± 0.6	NS	3.4 ± 0.2	2.8 ± 0.4	NS
Stent length, mm	18 ± 7.5	16 ± 5	18 ± 8	NS	11 ± 2	20 ± 8	NS
Affected vessel							
Anterior descending	19 (48)	5 (83)	4 (40)	NS	2 (50)	8 (40)	NS
Circumflex	6 (14)	0	2 (20)	NS	1 (25)	3 (15)	NS
Right coronary	15 (38)	1 (17)	4 (40)	NS	1 (25)	9 (45)	NS
Quantitative angiography							
Proximal reference diameter, mm	2.7 ± 0.5	3.2 ± 0.3	2.5 ± 0.4	*	2.4 ± 0.6	2.6 ± 0.6	NS
Minimal luminal diameter, mm	0.3 ± 0.6	0.4 ± 0.9	0.5 ± 0.8	NS	0.5 ± 1.1	0.1 ± 0.3	NS
Stenosis, %	89.6 ± 24.1	88.5 ± 28.2	82.8 ± 29.7	NS	77.5 ± 45	96.2 ± 11.1	NS
TIMI flow							
0	32 (80)	5 (83)	7 (70)	NS	3 (75)	17 (85)	NS
1	0	0	0	NS	0	0	NS
2	2 (5)	1 (17)	0	NS	0	1 (5)	NS
3	6 (15)	0	3 (30)	NS	1 (25)	2 (10)	NS
Antiplatelet therapy							
None	6 (15)	0	1 (10)	NS	1 (25)	4 (20)	NS
Single antiplatelet	16 (40)	0	0	NS	0	16 (80)	NS
Dual antiplatelet	18 (45)	6 (100)	9 (90)	NS	3 (75)	0	NS
Treatment before OCT							
None	8 (23)	2 (40)	2 (25)	NS	1 (25)	3 (17)	NS
Thrombus aspiration	17 (49)	2 (40)	2 (25)	NS	1 (25)	12 (66)	NS
Balloon dilatation	1 (3)	0	1 (12)	NS	0	0	NS
Both	9 (25)	1 (20)	3 (38)	NS	2 (50)	3 (17)	NS
ST treatment							
Medical treatment	4 (11)	0	2 (20)	NS	1 (25)	1 (5)	NS
Balloon dilatation	13 (33)	4 (66)	4 (40)	NS	1 (25)	4 (20)	NS
Reimplantation	18 (45)	2 (34)	4 (40)	NS	2 (50)	10 (50)	NS
Drug-eluting balloon	2 (5)	0	0	NS	0	2 (10)	NS
Death	6 (15)	2 (33)	1 (10)	NS	0	3 (15)	NS

AMI, acute myocardial infarction; CK, creatine kinase; DES, drug-eluting stent; hsTnT, high-sensitivity troponin T; NS, not significant; NSTEMI, non-ST-segment elevation myocardial infarction; OCT, optical coherence tomography; ST, stent thrombosis; STEMI, ST-segment elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.

Unless otherwise indicated, the data represent No. (%) or mean ± standard deviation.

* Significantly different ($P < .05$).




Figure 1. Stent thrombosis assessed using OCT. A: severe underexpansion of a bioabsorbable vascular device (arrows). B: areas of malapposition (dotted arrow) with associated thrombus. C: extensive areas of malapposition (dotted arrow) with a large thrombus burden (T). D: marked dissection (D) at the distal edge of a device implanted several hours before. E: extensive areas with coverage deficiency (dotted arrows) and other regions with slight malapposition. F: patient with very late ST whose OCT shows uncovered struts (dotted arrows). G-I: patients with very late ST with images of neoatherosclerosis with distal shadowing obscuring the stent struts; in addition, plaque rupture images with associated thrombus. Asterisks indicate shadowing caused by a wire artifact. OCT, optical coherence tomography; ST, stent thrombosis.

stent malapposition; e) in late STs, there was a high rate of uncovered and malapposed stents, findings that were highly prevalent in patients with a DES; and f) neoatherosclerosis was very frequent in patients with very late ST.

Optical coherence tomography has higher resolution than other intracoronary imaging techniques but has 2 clear limitations: lower imaging depth and the presence of shadowing behind thrombus images.¹³ Given these limitations, the use of OCT in clinical situations with a very large thrombus burden, such as ST, can be less useful.

Nonetheless, our results show that OCT is a safe and feasible technique in this challenging clinical setting. Due to its high resolution, despite the presence of residual thrombus in 85% of patients, an adequate analysis of the underlying anatomy was possible. The information provided greatly helped to reach a definitive diagnosis of the possible mechanisms involved.

In addition, systematic OCT study after interventional cardiology helped to guide the technique and optimize the final results.

Despite the relatively small size of the present series, this is, to our knowledge, the largest series involving the systematic analysis of OCT results after an intervention. Our findings indicate a very slight increase in the minimal stent area, a decrease in the SEI, a reduction in the maximal malapposition area and length, and a marked reduction in thrombus burden. Some previous studies—with fewer patients but using more aggressive OCT-guided optimization protocols—showed greater changes in the stent after the intervention.⁴ These differences might be due to the lack of strict optimization criteria and the strong association between underexpansion and highly severe vessel calcification. New studies are required to confirm if more aggressive optimization of stents that develop ST could improve the long-term clinical outcomes of these patients.

In 25% of our patients, plaque rupture was seen adjacent to stents with good coverage that had no evident mechanical problems in their interior. Although this phenomenon has already been reported, the previously reported cases were merely

Table 2
Analysis of Lesions by Optical Coherence Tomography Before and After Intervention for All Stent Thromboses

	All (n = 34)	Early ST (≤ 30 d) (n = 13)	Late ST (> 30 d) (n = 21)	P
<i>Before the intervention</i>				
Proximal reference area, mm ²	6.7 ± 2.2	6.5 ± 1.9	6.8 ± 2.4	NS
Proximal reference diameter, mm	2.9 ± 0.5	2.8 ± 0.4	2.9 ± 0.5	NS
Distal reference area, mm ²	5.3 ± 2.6	5.1 ± 2.9	5.4 ± 2.4	NS
Distal reference diameter, mm	2.5 ± 0.6	2.5 ± 0.7	2.6 ± 0.6	NS
Mean reference area, mm ²	6 ± 2.2	5.9 ± 2	6.1 ± 2.3	NS
Minimal luminal area, mm ²	1.9 ± 1.8	2.4 ± 2.6	1.6 ± 1.1	NS
Minimal stent area, mm ²	5.9 ± 2.6	5.4 ± 2.2	6 ± 2.6	NS
Stent expansion index < 80%	8 (23.5)	3 (23)	5 (23.8)	NS
Maximal thrombus area, mm ²	2.5 ± 1.6	2.6 ± 1.6	2.3 ± 1.6	NS
Maximal malapposition area, mm ²	0.9 ± 0.8	1.1 ± 1.1	0.8 ± 0.8	NS
Maximal malapposition length, mm	2.9 ± 1.7	3.7 ± 0.7	2.6 ± 2	NS
Plaque rupture adjacent to stent	10 (29.4)	2 (15.4)	8 (38.1)	NS
<i>After the intervention</i>				
Minimal stent area, mm ²	6 ± 2.7	5.8 ± 2.1	6.2 ± 3.1	NS
Stent expansion index < 80%	5 (14.7)	2 (15.4)	3 (14.2)	NS
Maximal thrombus area, mm ²	1.4 ± 1.5	1.7 ± 1.4	1 ± 1.6	NS
Maximal malapposition area, mm ²	0.5 ± 0.6	0.4 ± 0.3	0.5 ± 0.8	NS
Maximal malapposition length, mm	1.4 ± 1.7	1.6 ± 1.5	1.3 ± 1.9	NS

NS, not significant; ST, stent thrombosis.

Unless otherwise indicated, the data represent No. (%) or mean ± standard deviation.

anecdotal.¹⁶ The current angiographic criteria for the diagnosis of ST¹² are insufficient to detect this underlying phenomenon, which is why we believe OCT to be an indispensable tool for this diagnosis. In addition, the identification of this etiology can have important implications for the treatment of patients with ST. Thus, in these patients, management should be limited to treatment of the plaque rupture, with no need for a new intervention of the previously implanted stent.

By classifying the STs according to time, different pathophysiological mechanisms were identified, as already reported.^{17–19} The most frequent finding in patients with early ST was stent malapposition, for both acute and subacute STs. Kim et al.¹⁸ found a high rate of malapposed struts in asymptomatic patients, as well as a higher prevalence of thrombi associated with these regions of malapposition. There are no solid data showing irrefutable evidence that malapposition after stent implantation is associated with a higher rate of ST. Neither has it been shown that the use of aggressive postdilatation maneuvers to correct malapposition during the initial stent placement reduces adverse events during clinical follow-up.

Almost half of the patients with a late ST had uncovered struts, whereas 17% of them had malapposed struts. Previous autopsy studies found that the most frequent substrate in late ST is delayed or incomplete strut endothelialization.²⁰ Studies^{21,22} in patients with late ST determined that a mean 12% to 14% of struts were uncovered and that 4% to 6% were malapposed. In our series, the percentages of images showing uncovered or malapposed struts were slightly lower at 4.4% and 2.1%, respectively. This difference could be due to the later development of ST in our series than in the studies mentioned. Although the proportion of uncovered struts decreases over time, these data indicate that this phenomenon can be associated with the onset of ST even several years after stent implantation. A coverage deficiency or malapposition were more common with DESs. Some studies have already reported these findings.^{14,15} In our sample, this association could be due to

the shorter time from stent placement to ST for DESs than for BMSS (median, 740 days vs 3321 days; $P < .05$). In addition, late occurrence of malapposed struts (acquired malapposition) has been linked to positive vessel remodeling. Because our series lacked OCT data from after the implantation, we could not distinguish between persistent malapposition and acquired malapposition.

Finally, a high percentage of patients with late ST showed neoatherosclerosis. Previous studies have already reported that neoatherosclerosis might be a cause of late ST. In the study by Taniwaki et al.,²³ which performed OCT in 64 patients with late DES thrombosis, neoatherosclerosis was detected in 1 of every 4 patients. Again, the higher prevalence of neoatherosclerosis in our study could be due to the longer time elapsed between stent placement and ST.

Limitations

This study has several important limitations. First, there was no control group. Second, OCT could not be performed in some patients or the image quality was insufficient, which might have led to a selection bias. Currently, OCT does not permit confirmation of correct strut endothelialization because it cannot identify the type of tissue covering the struts. Thus, the term “strut coverage” was preferred in this study. A limitation inherent to the technique is the shadowing effect caused by red thrombi, which causes an unavoidable loss of anatomical information. In addition, evaluation of the degree of strut coverage can be particularly difficult in the presence of thrombi and a laminar thrombus can be indistinguishable from neointimal coverage. The results of the study may be limited by the inability to detect uncovered struts or those with incomplete apposition in regions with considerable thrombotic material. Nonetheless, most patients could be analyzed or provided sufficient information to permit diagnosis. Finally, the




Figure 2. Angiography and OCT of a patient with late ST secondary to plaque rupture adjacent to the stent. A: thrombotic occlusion of the anterior descending artery (arrow) proximal to the stent (continuous line). B: image of plaque rupture (arrow) adjacent to the stent. C: proximal edge of a completely covered stent, with images of a small thrombus (dotted arrow). D: nonocclusive neoatherosclerosis without indicators of intimal rupture. E: longitudinal cross-section showing the transversal sections corresponding to those of letters B to D. OCT, optical coherence tomography; ST, stent thrombosis. Asterisks indicate shadowing caused by a wire artifact.




Figure 3. Mechanisms of early stent thrombosis. ST, stent thrombosis.

Table 3
Strut Coverage and Malapposition Values Studied by Optical Coherence Tomography in Late Stent Thromboses

	Late STs	Bare-metal stents	Drug-eluting stents	
No. of cross-sections analyzed	3885	1920	1965	
Patients with some cross-sections with uncovered struts	11 (46)	3 (25)	8 (67)	<i>P</i> < .05
Patients with some cross-sections with malapposed struts	4 (17)	0	4 (33)	<i>P</i> < .05
Coverage				
Cross-sections with uncovered struts, no.	168	31	137	<i>P</i> < .05
Cross-sections with uncovered struts, %	4.4 ± 8	1.1 ± 2	7.7 ± 10.3	<i>P</i> < .05
Apposition				
Cross-sections with malapposed struts, no.	79	0	79	<i>P</i> < .05
Cross-sections with malapposed struts, %	2.1 ± 5.1	0	4.2 ± 6.7	<i>P</i> < .05

ST, stent thrombosis.

Unless otherwise indicated, data are expressed as No. (%) or mean ± standard deviation.

lack of a baseline OCT study meant that we could not distinguish between persistent and acquired malapposition.

CONCLUSIONS

For patients who experience ST, OCT is a safe and feasible technique that provides crucial information to establish an accurate diagnosis and guide treatment. Rupture of plaques adjacent to the stent is not infrequent, although, in angiography, it is indistinguishable from a ST originating in the stent. In early STs, the most frequently associated mechanism is malapposition. In late STs, uncovered and malapposed struts and neoatherosclerosis are often seen, particularly in DESs.

FUNDING

This study was partially funded by the 7th European Framework Program PRESTIGE (PREvention of late Stent Thrombosis by an interdisciplinary Global European effort) (project number: 260309).

CONFLICTS OF INTEREST

None declared.

WHAT IS KNOWN ABOUT THE TOPIC?

- Stent thrombosis is a serious complication in interventional cardiology. Intracoronary imaging techniques provide crucial data for diagnosis and intervention guidance. Few data are available on the use of OCT for this condition.

WHAT DOES THIS STUDY ADD?

- Optical coherence tomography of ST is a safe and feasible technique that provides singular information on the underlying pathophysiological mechanisms and can help to guide interventions.

REFERENCES

1. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic

Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*. 2014;35:2541–2619.

2. Jiménez-Quevedo P, Serrador A, Pérez de Prado A, Pan M. Spanish Cardiac Catheterization and Coronary Intervention Registry 25th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2015). *Rev Esp Cardiol*. 2016;69:1180–1189.
3. Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). *Circulation*. 2010;122:52–61.
4. Alfonso F, Dutary J, Paulo M, et al. Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis. *Heart*. 2012;98:1213–1220.
5. Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. *JACC Cardiovasc Interv*. 2012;5:131–140.
6. Byrne RA, Serruys PW, Baumbach A, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. *Eur Heart J*. 2015;36:2608–2620.
7. Alfonso F, Suárez A, Pérez-Vicayno MJ, et al. Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. *J Am Coll Cardiol*. 2007;50:2095–3007.
8. Fuji K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. *J Am Coll Cardiol*. 2005;45:995–998.
9. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. *Circulation*. 2007;115:2426–2434.
10. Finn AV, Otsuka F. Neoatherosclerosis: a culprit in very late stent thrombosis. *Circ Cardiovasc Interv*. 2012;5:6–9.
11. Cuesta J, Rivero F, Alfonso F. Ongoing stent thrombosis: optical coherence tomography findings. *Rev Esp Cardiol*. 2015;68:1024.
12. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stents trials: a case for standardized definitions. *Circulation*. 2007;115:2344–2351.
13. Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. *Eur Heart J*. 2010;31:401–415.
14. Kang SJ, Lee CW, Song H, et al. OCT analysis in patients with very late stent thrombosis. *JACC Cardiovasc Imaging*. 2013;6:695–703.
15. Amioka M, Shiode N, Kawase T, et al. Causes of very late stent thrombosis investigated using optical coherence tomography. *Intern Med*. 2014;53:2031–2039.
16. Alfonso F, Gonzalo N, Hernández R. A rare cause of late drug-eluting stent thrombosis unraveled by optical coherence tomography. *Circ Cardiovasc Interv*. 2011;4:399–400.
17. Souteyrand G, Amabile N, Mangin L. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. *Eur Heart J*. 2016;37:1208–1216.
18. Kim JS, Hong MK, Fan C, et al. Intracoronary thrombus formation after drug-eluting stents implantation: optical coherence tomographic study. *Am Heart J*. 2010;159:278–283.
19. Wijns W, Shite J, Jones MR, et al. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILLUMIEN I study. *Eur Heart J*. 2015;36:3346–3355.

20. Joner M, Finn AV, Farb A. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. *J Am Coll Cardiol*. 2006;48:193–202.
21. Parodi G, La Manna A, Di Vito L, et al. Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. *Eurointervention*. 2013;9:936–944.
22. Guagliumi G, Sirbu V, Musumeci G, et al. Examination of the in vivo mechanism of late drug-eluting stent thrombosis. *JACC Cardiovasc Interv*. 2012;5:12–20.
23. Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. *Circulation*. 2016;133:650–660.